Rafael Holdings Inc. (NYSE: RFL) originated as a corporate spin-off from Trammell Crow Company and subsequent real estate and pharmaceutical asset divisions. Over its operating history on public exchanges, the company transitioned its primary focus toward clinical-stage biopharmaceutical development, investing heavily in oncology and metabolic drug candidates while retaining legacy commercial real estate properties and corporate holdings.